Mohamedein A, Yousif-Kadaru A G, Ahmed S A, Saida H, Zaki Z A, Fedail S S
Department of Biochemistry, Faculty of Medicine, University of Khartoum, Sudan.
East Afr Med J. 1995 Sep;72(9):584-7.
The clinical usefulness of plasma abnormal prothrombin, defined as protein induced by vitamin K absence or antagonist II: (PIVKA II) as a tumour marker for hepatocellular carcinoma (HCC) and other liver diseases has been evaluated. PIVKA II concentrations were determined using an enzyme-linked immunosorbent assay (ELISA) with monoclonal antibody that reacts with PIVKA II but does not cross-react with normal prothrombin. Seventy four patients (74%) out of 100 with HCC had abnormal PIVKA II levels above 0.5 AU/ml (median = 3.4 AU/ml). The level was above 1.0 AU/ml in 66 (66%) of the patients. In contrast the level of PIVKA II was low in patients with bilharzial periportal fibrosis (median = 0.09 AU/ml), patients with liver cirrhosis (median = 0.13 AU/ml), patients with hepatitis (median = 0.025 AU/ml), and essentially undetectable in all the 34 controls. The diagnostic ability of serum alphafoetoprotein (AFP) was also evaluated in these patients. AFP alone can diagnose 51% of the HCC cases. Of the remaining patients with low or negative AFP levels (65%) can be diagnosed using PIVKA II. Abnormal prothrombin is a potential marker for the laboratory diagnosis of hepatocellular carcinoma.
已对血浆异常凝血酶原（定义为维生素K缺乏或拮抗剂II诱导的蛋白质：PIVKA II）作为肝细胞癌（HCC）和其他肝脏疾病肿瘤标志物的临床实用性进行了评估。使用与PIVKA II反应但不与正常凝血酶原交叉反应的单克隆抗体通过酶联免疫吸附测定（ELISA）来测定PIVKA II浓度。100例HCC患者中有74例（74%）的PIVKA II水平异常，高于0.5 AU/ml（中位数 = 3.4 AU/ml）。66例（66%）患者的该水平高于1.0 AU/ml。相比之下，血吸虫性门静脉周围纤维化患者（中位数 = 0.09 AU/ml）、肝硬化患者（中位数 = 0.13 AU/ml）、肝炎患者（中位数 = 0.025 AU/ml）的PIVKA II水平较低，并且在所有34名对照中基本检测不到。还对这些患者血清甲胎蛋白（AFP）的诊断能力进行了评估。单独AFP可诊断51%的HCC病例。其余AFP水平低或为阴性的患者（65%）可使用PIVKA II进行诊断。异常凝血酶原是肝细胞癌实验室诊断的潜在标志物。
